MiMedx Group, Inc (MDXG) — Analysis Summary
MiMedx Group, Inc (MDXG) has a market cap of $625.57M with year-over-year revenue growth of +20.0%. Net margin stands at 11.6%. The stock trades at a P/E ratio of 20.4.
Key Takeaways
- Revenue changed +20.0% year-over-year
- Net margin of 11.6%
- P/E ratio of 20.4
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, MDXG posted revenue growth of +20.0% and trades at a P/E of 20.4.
MiMedx Group, Inc (MDXG)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
808
Headquarters
MARIETTA, GA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.